Glypican-3-specific T-cell receptor and its uses for immunotherapy of hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the third most common cause of cancer related death worldwide. Cure of HCC is only possible by complete resection in early stages, but only 10–20% of tumors can be curatively resected and the risk of HCC recurrence is high. In addition, HCC is resistant to conventional radio- or chemotherapy. As a result, the prognosis of HCC remains poor and new therapies are urgently needed. The discovery of so far unknown immunodominant epitopes of the tumor-associated antigen Glypican-3 and the according HLA-A2 restricted T-cell-receptor enable the development of an adoptive T cell therapy for HCC patients. Adoptive T cell therapies showed very promising results in cancer therapy over the last years. The Science Magazine even awarded this technology as “Breakthrough of the year 2013”. Therefore, the current invention provides the tools for a promising new approach for the therapy of HCC.

Further information: PDF

Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0

Contact
Peer Biskup

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.